Waters Corporation (0LTI.L)
USD 325.39
(-5.2%)
USD 325.39
(-5.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.47 Billion USD | 25.19% |
| 2022 | 2.77 Billion USD | 1.82% |
| 2021 | 2.72 Billion USD | 4.59% |
| 2020 | 2.6 Billion USD | -5.97% |
| 2019 | 2.77 Billion USD | 28.39% |
| 2018 | 2.16 Billion USD | -30.44% |
| 2017 | 3.1 Billion USD | 31.59% |
| 2016 | 2.36 Billion USD | 7.17% |
| 2015 | 2.2 Billion USD | 11.0% |
| 2014 | 1.98 Billion USD | 9.5% |
| 2013 | 1.81 Billion USD | 6.54% |
| 2012 | 1.7 Billion USD | 13.64% |
| 2011 | 1.49 Billion USD | 18.89% |
| 2010 | 1.25 Billion USD | 17.82% |
| 2009 | 1.06 Billion USD | 11.08% |
| 2008 | 961.89 Million USD | -25.72% |
| 2007 | 1.29 Billion USD | 3.19% |
| 2006 | 1.25 Billion USD | 9.57% |
| 2005 | 1.14 Billion USD | 46.51% |
| 2004 | 781.74 Million USD | 44.66% |
| 2003 | 540.38 Million USD | 56.34% |
| 2002 | 345.63 Million USD | 13.26% |
| 2001 | 305.16 Million USD | 26.85% |
| 2000 | 240.56 Million USD | -17.67% |
| 1999 | 292.2 Million USD | -30.18% |
| 1998 | 418.5 Million USD | -13.12% |
| 1997 | 481.7 Million USD | 60.3% |
| 1996 | 300.5 Million USD | 27.6% |
| 1995 | 235.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.9 Billion USD | -4.23% |
| 2024 Q2 | 3.03 Billion USD | -6.62% |
| 2024 Q1 | 3.25 Billion USD | -6.45% |
| 2023 Q4 | 3.47 Billion USD | -3.21% |
| 2023 Q2 | 3.77 Billion USD | 39.53% |
| 2023 FY | 3.47 Billion USD | 25.19% |
| 2023 Q1 | 2.7 Billion USD | -2.52% |
| 2023 Q3 | 3.59 Billion USD | -4.91% |
| 2022 Q1 | 2.66 Billion USD | -2.24% |
| 2022 FY | 2.77 Billion USD | 1.82% |
| 2022 Q4 | 2.77 Billion USD | 3.43% |
| 2022 Q3 | 2.68 Billion USD | 1.37% |
| 2022 Q2 | 2.64 Billion USD | -0.67% |
| 2021 FY | 2.72 Billion USD | 4.59% |
| 2021 Q1 | 2.98 Billion USD | 14.3% |
| 2021 Q4 | 2.72 Billion USD | -3.31% |
| 2021 Q2 | 2.83 Billion USD | -4.87% |
| 2021 Q3 | 2.82 Billion USD | -0.52% |
| 2020 Q3 | 2.72 Billion USD | -4.2% |
| 2020 Q4 | 2.6 Billion USD | -4.16% |
| 2020 FY | 2.6 Billion USD | -5.97% |
| 2020 Q1 | 3 Billion USD | 8.34% |
| 2020 Q2 | 2.84 Billion USD | -5.47% |
| 2019 FY | 2.77 Billion USD | 28.39% |
| 2019 Q4 | 2.77 Billion USD | 13.39% |
| 2019 Q1 | 2.28 Billion USD | 5.64% |
| 2019 Q3 | 2.44 Billion USD | 7.9% |
| 2019 Q2 | 2.26 Billion USD | -0.67% |
| 2018 Q3 | 2.16 Billion USD | -0.73% |
| 2018 Q1 | 2.37 Billion USD | -23.54% |
| 2018 Q4 | 2.16 Billion USD | -0.3% |
| 2018 FY | 2.16 Billion USD | -30.44% |
| 2018 Q2 | 2.18 Billion USD | -8.08% |
| 2017 Q1 | 2.41 Billion USD | 2.36% |
| 2017 Q4 | 3.1 Billion USD | 22.57% |
| 2017 Q3 | 2.53 Billion USD | 2.25% |
| 2017 Q2 | 2.47 Billion USD | 2.58% |
| 2017 FY | 3.1 Billion USD | 31.59% |
| 2016 Q2 | 2.29 Billion USD | 1.41% |
| 2016 FY | 2.36 Billion USD | 7.17% |
| 2016 Q4 | 2.36 Billion USD | 1.83% |
| 2016 Q3 | 2.31 Billion USD | 0.82% |
| 2016 Q1 | 2.26 Billion USD | 2.92% |
| 2015 Q3 | 2.15 Billion USD | 2.69% |
| 2015 Q4 | 2.2 Billion USD | 2.3% |
| 2015 Q1 | 2.01 Billion USD | 1.33% |
| 2015 Q2 | 2.09 Billion USD | 4.27% |
| 2015 FY | 2.2 Billion USD | 11.0% |
| 2014 Q4 | 1.98 Billion USD | 3.89% |
| 2014 Q1 | 1.83 Billion USD | 1.01% |
| 2014 Q2 | 1.88 Billion USD | 2.93% |
| 2014 Q3 | 1.9 Billion USD | 1.37% |
| 2014 FY | 1.98 Billion USD | 9.5% |
| 2013 Q2 | 1.76 Billion USD | 2.0% |
| 2013 FY | 1.81 Billion USD | 6.54% |
| 2013 Q4 | 1.81 Billion USD | 0.3% |
| 2013 Q3 | 1.8 Billion USD | 2.34% |
| 2013 Q1 | 1.73 Billion USD | 1.77% |
| 2012 Q1 | 1.55 Billion USD | 3.69% |
| 2012 Q2 | 1.62 Billion USD | 4.45% |
| 2012 Q3 | 1.66 Billion USD | 2.86% |
| 2012 Q4 | 1.7 Billion USD | 2.01% |
| 2012 FY | 1.7 Billion USD | 13.64% |
| 2011 Q2 | 1.34 Billion USD | 3.85% |
| 2011 FY | 1.49 Billion USD | 18.89% |
| 2011 Q1 | 1.29 Billion USD | 2.98% |
| 2011 Q3 | 1.48 Billion USD | 9.97% |
| 2011 Q4 | 1.49 Billion USD | 1.09% |
| 2010 Q1 | 1.16 Billion USD | 10.31% |
| 2010 FY | 1.25 Billion USD | 17.82% |
| 2010 Q4 | 1.25 Billion USD | -1.83% |
| 2010 Q3 | 1.28 Billion USD | 4.82% |
| 2010 Q2 | 1.22 Billion USD | 4.73% |
| 2009 Q2 | 1.07 Billion USD | 6.25% |
| 2009 FY | 1.06 Billion USD | 11.08% |
| 2009 Q4 | 1.05 Billion USD | -4.16% |
| 2009 Q3 | 1.1 Billion USD | 3.08% |
| 2009 Q1 | 1 Billion USD | 4.88% |
| 2008 Q2 | 1.41 Billion USD | 4.15% |
| 2008 FY | 961.89 Million USD | -25.72% |
| 2008 Q4 | 961.89 Million USD | -34.06% |
| 2008 Q1 | 1.35 Billion USD | 4.82% |
| 2008 Q3 | 1.45 Billion USD | 3.18% |
| 2007 Q2 | 1.28 Billion USD | 2.76% |
| 2007 Q4 | 1.29 Billion USD | -2.38% |
| 2007 Q3 | 1.32 Billion USD | 2.99% |
| 2007 Q1 | 1.25 Billion USD | -0.11% |
| 2007 FY | 1.29 Billion USD | 3.19% |
| 2006 Q1 | 1.18 Billion USD | 3.07% |
| 2006 Q3 | 1.24 Billion USD | 1.76% |
| 2006 Q4 | 1.25 Billion USD | 1.16% |
| 2006 FY | 1.25 Billion USD | 9.57% |
| 2006 Q2 | 1.21 Billion USD | 3.26% |
| 2005 Q2 | 973.19 Million USD | 7.68% |
| 2005 Q4 | 1.14 Billion USD | 14.52% |
| 2005 FY | 1.14 Billion USD | 46.51% |
| 2005 Q1 | 903.77 Million USD | 15.61% |
| 2005 Q3 | 1 Billion USD | 2.77% |
| 2004 Q2 | 718.94 Million USD | 7.06% |
| 2004 Q3 | 699.7 Million USD | -2.68% |
| 2004 Q1 | 671.56 Million USD | 24.28% |
| 2004 FY | 781.74 Million USD | 44.66% |
| 2004 Q4 | 781.74 Million USD | 11.72% |
| 2003 Q3 | 467.22 Million USD | 15.53% |
| 2003 Q1 | 439.95 Million USD | 27.29% |
| 2003 FY | 540.38 Million USD | 56.34% |
| 2003 Q4 | 540.38 Million USD | 15.66% |
| 2003 Q2 | 404.4 Million USD | -8.08% |
| 2002 FY | 345.63 Million USD | 13.26% |
| 2002 Q4 | 345.63 Million USD | 7.19% |
| 2002 Q3 | 322.44 Million USD | 1.13% |
| 2002 Q2 | 318.82 Million USD | 1.18% |
| 2002 Q1 | 315.09 Million USD | 3.25% |
| 2001 Q4 | 305.16 Million USD | 22.17% |
| 2001 FY | 305.16 Million USD | 26.85% |
| 2001 Q2 | 248.34 Million USD | 9.93% |
| 2001 Q1 | 225.9 Million USD | -6.09% |
| 2001 Q3 | 249.77 Million USD | 0.58% |
| 2000 FY | 240.56 Million USD | -17.67% |
| 2000 Q1 | 261.32 Million USD | -10.57% |
| 2000 Q2 | 212.96 Million USD | -18.51% |
| 2000 Q3 | 222.14 Million USD | 4.31% |
| 2000 Q4 | 240.56 Million USD | 8.29% |
| 1999 Q4 | 292.2 Million USD | -4.23% |
| 1999 FY | 292.2 Million USD | -30.18% |
| 1999 Q1 | 369.2 Million USD | -11.78% |
| 1999 Q2 | 331.3 Million USD | -10.27% |
| 1999 Q3 | 305.1 Million USD | -7.91% |
| 1998 Q1 | 477.6 Million USD | -0.85% |
| 1998 FY | 418.5 Million USD | -13.12% |
| 1998 Q2 | 457 Million USD | -4.31% |
| 1998 Q3 | 437.6 Million USD | -4.25% |
| 1998 Q4 | 418.5 Million USD | -4.36% |
| 1997 Q2 | 275 Million USD | -4.94% |
| 1997 Q3 | 503 Million USD | 82.91% |
| 1997 Q4 | 481.7 Million USD | -4.23% |
| 1997 FY | 481.7 Million USD | 60.3% |
| 1997 Q1 | 289.3 Million USD | -3.73% |
| 1996 FY | 300.5 Million USD | 27.6% |
| 1996 Q1 | 223.7 Million USD | -5.01% |
| 1996 Q2 | 321.7 Million USD | 43.81% |
| 1996 Q4 | 300.5 Million USD | -4.97% |
| 1996 Q3 | 316.2 Million USD | -1.71% |
| 1995 Q1 | 340 Million USD | 0.0% |
| 1995 Q4 | 235.5 Million USD | -31.48% |
| 1995 Q2 | 348.7 Million USD | 2.56% |
| 1995 FY | 235.5 Million USD | 0.0% |
| 1995 Q3 | 343.7 Million USD | -1.43% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -457.117% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -2656.971% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -462.81% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -1213.205% |
| bluebird bio, Inc. | 424.62 Million USD | -718.727% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -4956.084% |
| Imunon, Inc. | 8.53 Million USD | -40654.267% |
| Editas Medicine, Inc. | 150.05 Million USD | -2216.81% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 83.098% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 0.827% |
| Myriad Genetics, Inc. | 312.9 Million USD | -1011.062% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -241.035% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -613.188% |
| Verastem, Inc. | 71.18 Million USD | -4783.772% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 94.951% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 93.299% |
| Biogen Inc. | 12.04 Billion USD | 71.138% |
| Nektar Therapeutics | 267.04 Million USD | -1201.841% |
| Perrigo Company plc | 6.04 Billion USD | 42.453% |
| Dynavax Technologies Corporation | 375.02 Million USD | -827.011% |
| Illumina, Inc. | 4.36 Billion USD | 20.373% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -9782.883% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -1676.105% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -1255.477% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -9222.41% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -83.937% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -4117.38% |
| Evolus, Inc. | 209.68 Million USD | -1557.954% |
| Adicet Bio, Inc. | 37.12 Million USD | -9265.606% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -8542.453% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 51.084% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -426.115% |
| FibroGen, Inc. | 585.72 Million USD | -493.537% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 29.31% |
| OPKO Health, Inc. | 622.47 Million USD | -458.495% |
| Homology Medicines, Inc. | 118.53 Million USD | -2832.949% |
| Geron Corporation | 146.12 Million USD | -2279.104% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 14.171% |
| Exelixis, Inc. | 678.44 Million USD | -412.424% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -17221.075% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -27636.66% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -1286.125% |
| Zoetis Inc. | 9.29 Billion USD | 62.598% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -775.125% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -6969.532% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 32.492% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -7076.206% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -33.538% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -44.539% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -2928.005% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -110.766% |
| Blueprint Medicines Corporation | 918.64 Million USD | -278.441% |
| Insmed Incorporated | 1.66 Billion USD | -109.207% |
| TG Therapeutics, Inc. | 169.08 Million USD | -1956.074% |
| Incyte Corporation | 1.59 Billion USD | -118.337% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -193.228% |